Genome BC Invests C$750K in Startup Microbiome Insights

Dec 06, 2017

|

NEW YORK (GenomeWeb) – Genome BC said today that it is investing C$750,000 ($586,000) in Microbiome Insights (MBI), a Vancouver-based microbiome testing company.

MBI provides next-generation sequencing-based analytical testing and consulting services to microbiome researchers in academia and industry.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

Menu

Genome BC Invests C$750K in Startup Microbiome Insights

To read the full story....

Breaking News

Thermo Fisher Preliminary Q1 Revenues up 1 to 2 Percent; Firm Withdraws 2020 Guidance

Luminex Receives Emergency Use Authorization for Second SARS-CoV-2 Assay

ScienCell SARS-CoV-2 Test Gets FDA Emergency Use Authorization

Co-Diagnostics Gets Emergency Use Authorization for Coronavirus Test

Myriad Genetics BRCA Test to be Reimbursed in Japan

With Sputum Test for SARS-CoV-2, MicroGen Dx Aims to Challenge Quest, LabCorp

The Scan

German Shepherd's Own Sequence

And Now Serology Tests

Young at Brain

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

What's Popular?

LexaGene Shifts Gears to Prepare Viral RT-qPCR Panel for FDA Emergency Submission

Co-Diagnostics Gets Emergency Use Authorization for Coronavirus Test

Thermo Fisher Preliminary Q1 Revenues up 1 to 2 Percent; Firm Withdraws 2020 Guidance

Color Gears Up to Enter COVID-19 Testing Space

A. Menarini to Distribute Credo Diagnostics Coronavirus Assay Kit, Respiratory Infection Assays

Sponsorships